Information  X 
Enter a valid email address

Hikma Pharm Ord Shs 10P (HIK)

Related News

30-Apr-2021 07:43 AM

Hikma Pharmaceuticals lifts guidance on generics business amid 'good' start to year

Pharmaceuticals group Hikma Pharmaceuticals forecast its generics business to generate revenue toward the top end of guidance following a 'good' start to the new year that was in line with its expectations. Full year generics revenue was now e
25-Feb-2021 08:16 AM

Hikma Pharmaceuticals annual profit rises on injectables sales growth

Pharmaceutical company Hikma Pharmaceuticals reported a rise in profit led by growth in its injectables business. For the year ended 31 December 2020, pre-tax profit rose to $558 million from $491 million last year and revenue to rise 6% to $2.34 bill
05-Nov-2020 08:05 AM

Hikma Pharmaceuticals lifts guidance on generics business on strong YTD performance

Hikma Pharmaceuticals lifted its full-year guidance on revenue for its generics segment following stronger-than-expected performance in the year to date. Revenue for generics was lifted to a range of $720 million to $740 million, from previous guidance r
04-Sep-2020 08:20 AM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to overweight (from equal weight) and raised its price target to 2800p (from 2350p). Story provided by StockMarketWire.com Broker Forecasts data provided by www
14-Aug-2020 09:20 AM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2350p (from 2200p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.u
07-Aug-2020 07:35 AM

Hikma Pharmaceuticals lifts outlook on injectables amid first-half profit beat

Generic pharmaceuticals company Hikma Pharmaceuticals upgraded its outlook on its injectable business after first-half results came in ahead of its expectations on increased demand for Covid-19-related products. For the six months ended 30 June, pre-tax
30-Jul-2020 08:30 AM

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2860p (from 2380p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
07-Jul-2020 11:00 AM

Broker Forecast - Morgan Stanley issues a broker note on Hikma Pharmaceuticals PLC

Morgan Stanley today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to overweight (from equal weight) and raised its price target to 2600p (from 2200p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.s
30-Apr-2020 07:45 AM

Hikma Pharmaceuticals maintains guidance amid 'strong' start to year

Hikma Pharmaceuticals maintained its guidance and said it had made a 'strong start' to the year despite the challenging market conditions owing to the Covid-19 crisis. The company reiterating its guidance for global injectables revenue growth
28-Apr-2020 11:30 AM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2200p (from 1950p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.u
24-Apr-2020 10:40 AM

Broker Forecast - Goldman Sachs issues a broker note on Hikma Pharmaceuticals PLC

Goldman Sachs today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to neutral (from buy) and raised its price target to 2400p (from 2200p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagaz
07-Apr-2020 10:30 AM

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from buy). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
03-Apr-2020 09:50 AM

Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC

Citigroup today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2500p (from 2150p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
02-Apr-2020 10:20 AM

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC

Peel Hunt today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from hold) and raised its price target to 2380p (from 1990p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk.
31-Mar-2020 09:00 AM

Hikma Pharmaceuticals wins ruling to sell, make generic version of Amarin's heart drug

Generic pharmaceutical company Hikma Pharmaceuticals said a U.S. ruled that patents covering Amarin's heart drug were invalid, paving the way for the company to sell generic versions of the drug. Hikma said it was working closely with the U.S. Food
12-Mar-2020 12:50 PM

Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC

Jefferies International today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2390p (from 2300p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk.
10-Mar-2020 12:50 PM

Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC

Citigroup today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from neutral) and raised its price target to 2150p (from 1980p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.
02-Mar-2020 01:50 PM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1950p (from 1900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.u
27-Feb-2020 09:24 AM

Hikma Pharmaceuticals profit rises on cost cuts, revenue growth

Hikma Pharmaceuticals reported a rise in profit as cost cuts and higher revenue underpinned performance. For the year ended 31 December 2019, pre-tax profit rose to £49m1 from £293m on-year as revenue climbed 7% to £2.2bn. The inject
17-Feb-2020 10:10 AM

Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC

Citigroup today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to neutral (from buy). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
21-Jan-2020 10:30 AM

Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC

Jefferies International today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 2240p (from 2310p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
06-Jan-2020 10:40 AM

Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to underweight (from neutral) and raised its price target to 1850p (from 1800p). Story provided by StockMarketWire.com Broker Forecasts data provided by ww
03-Dec-2019 10:10 AM

Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1800p (from 1700p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk..
07-Nov-2019 07:16 AM

Hikma Pharmaceuticals says revenue from generics business to be at top end of range

Hikma Pharmaceuticals said it expected revenues in its generics business to be closer to the top end of its guidance range following strong demand and operational improvements. For the full year, the pharma company said it now expected generics revenue
20-Aug-2019 08:40 AM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1900p (from 1800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.u

a d v e r t i s e m e n t